<p>The absolute bioavailability oral capsules after a dose was 89% in one pharmacokinetic study. Cmax was reached 5–6 hours after administration of a single dose given after the first meal of the day. The Cmax doubled when the drug was administered in the fasting state. Despite this, meloxicam can be taken without regard to food, unlike many other NSAIDS.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Bekker A, Kloepping C, Collingwood S: Meloxicam in the management of post-operative pain: Narrative review. J Anaesthesiol Clin Pharmacol. 2018 Oct-Dec;34(4):450-457. doi: 10.4103/joacp.JOACP_133_18. (PubMed ID 30774225)" href="#reference-A190189">1</a>,<a class="reference-popover-link" data-content="FDA approved products: Mobic (meloxicam) oral tablets" href="#reference-L11398">10</a></sup></p><p>Meloxicam formulated for instillation with <a href="https://go.drugbank.com/drugs/DB00297">bupivacaine</a> produced varied systemic measures following a single dose of varying strength. In patients undergoing bunionectomy, 1.8 mg of meloxicam produced a C<sub>max</sub> of 26 ± 14 ng/mL, a median T<sub>max</sub> of 18 h, and an AUC<sub>∞</sub> of 2079 ± 1631 ng*h/mL. For a 9 mg dose used in herniorrhaphy, the corresponding values were 225 ± 96 ng/mL, 54 h, and the AUC<sub>∞</sub> was not reported. Lastly, a 12 mg dose used in total knee arthroplasty produced values of 275 ± 134 ng/mL, 36 h, and 25,673 ± 17,666 ng*h/mL.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: ZYNRELEF (bupivacaine and meloxicam) extended-release solution for injection" href="#reference-L34100">13</a></sup></p>